by admin | Aug 5, 2015 | Press Releases
SEATTLE (August 5, 2015) – Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, announced an average survival increase of 11 months in end-stage colorectal cancer patients in Cancer Immunology,...
by admin | Jul 20, 2015 | Press Releases
SEATTLE – (July 20, 2015) – Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, has added Dr. Thomas Caskey to its Board of Directors and Drs. / Jerome Zeldis, Slobodan Paessler to its...
by admin | Jul 9, 2015 | Press Releases
SEATTLE – (July 9, 2015) – Etubics Corporation, a privately-held, clinical stage biotechnology company developing an immunotherapy vaccine platform, announced today that it has retained Gerald L. Messerschmidt, MD, FACP as Chief Medical Officer. The company is...
by admin | Jun 23, 2015 | Press Releases
SEATTLE – (June 23, 2015) – Etubics Corporation, a privately held clinical stage biotechnology company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an Institute of...
by admin | May 28, 2014 | Press Releases
SEATTLE (May 28, 2014) – Etubics Corporation, a clinical stage biotechnology company with a proprietary platform technology that delivers a long lasting “active” immune response against diseases, will present clinical data from its Phase 1/2 proof of...
